L 888607

Cat. No.: HY-111271

CAS No.: 860033-06-3

Molecular Formula: $C_{19}H_{15}ClFNO_2S$

Molecular Weight: 375.84

Target: Prostaglandin Receptor

Pathway: GPCR/G Protein

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (266.07 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6607 mL	13.3035 mL	26.6071 mL
	5 mM	0.5321 mL	2.6607 mL	5.3214 mL
	10 mM	0.2661 mL	1.3304 mL	2.6607 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (6.65 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (6.65 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

L 888607 is a potent, selective, stable and orally active CRTH2 agonist. L 888607 has high affinity for the human CRTH2 receptor with a K_i value of 4 nM. L 888607 can be used for the research of several physiological events and metabolite[1].

IC_{50} & Target

DP	TP Receptor	FP Receptor	IP Receptor
0.8 nM (Ki)	283 nM (Ki)	10018 nM (Ki)	14434 nM (Ki)

In Vitro

L 888607 has high affinity for the human CRTH2 receptor with a K_i value of 4 nM[1].
L 888607 has some affinity for the human DP receptor with a K_i value of 211 nM[1].
L 888607 displays a relatively high selectivity for CRTH2 receptor[1].
L 888607 has agonistic activity on recombinant and endogenously expressed CRTH2 receptor with an EC_{50} value of 0.4 nM[1].

L 888607(100 nM, 20 min) stimulates eosinophil chemotaxis[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence[1]

Cell Line:	human eosinophils
Concentration:	100 nM
Incubation Time:	20 min
Result:	Significantly stimulated the migration of eosinophils to the bottom chamber.

In Vivo

L 888607 (i.v., 5 mg/kg, single or oral, 20 mg/kg, single) shows relative stability in vivo[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male (ICR)BR mice[1]
Dosage:	5 mg/kg, 20 mg/kg
Administration:	i.v., 5 mg/kg, single or oral, 20 mg/kg, single
Result:	Showed no obvious side effect.

CUSTOMER VALIDATION

- Cell. 2023 Dec 7;186(25):5500-5516.e21.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Gervais FG, Identification of a potent and selective synthetic agonist at the CRTH2 receptor. Mol Pharmacol. 2005 Jun;67(6):1834-9.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA